Depending on macro conditions, we still could see the upper 30s before next Tuesday.
Where we go from there will be driven by 2015 milestone announcements next week.
Sorry to hear this.
It sounds like you bought at very inopportune times, as there were plenty of occasions to get the stock cheaper than it is today during the last two years.
If I were you, I would have waited to hear the guidance for 2015 company out next week. I wouldn't have sold near the yearly low. But, to each his own.
Sal, I'm not sure I understand you.
You indicate that the only reason to own this stock is to wait on when the criminals want to move it higher? Is that the investment thesis to follow? And not the real data?
I will add to this that the ONLY thing that will lead to a SUSTAINABLE higher PPS for ONCS is a true PARTNERSHIP with big pharma, where money is paid UP FRONT with milestones for additional money.
Interim P2B data results likely won't be available until Q3. That's the only data release which could materially move the stock with any sustaining power.
Until then, we will likely be range bound between 0.35 and 0.50. There are simply are no significant catalysts on the near-term horizon.
I'm holding for now, as I expect it to trade upwards to 0.50 in the short-term, Sal. Like everyone else on this forum, I reserve the right to change my mind at any time (as others have done countless times). But those are my thoughts now, based on what is known in the public domain. And by the way, I'm not stupid. Want to debate that?
Everyone's time horizon for investing is different. Look at what ADXS and ZIOP have both done in the last 6 weeks.
The thing that worries me the most is the TINY size of the upcoming "pilot" trials. Those typically don't lead to partnerships. That's my biggest concern, especially when it's almost certain the FDA won't fast-track a device or protocol with only a 10 patient trial. And for those who believe otherwise, I invite you to "show us the money," by showing us previous results which led to such an decision by the FDA.
Yes, we're talking about REAL and long-term SUSTAINABLE shareholder value based on MATERIAL positive events of significant and sufficient magnitude.
Not a company where the stock price can apparently instead be controlled by a band of criminals in the OTC marketplace?
No, you're making a fool of yourself in public for the entire world to see. LMAO!
And most of us are making more money than you can dream of.
Dream on, turkey lips... you imp. (And that's being kind.)
The only blood we see is yours.
And guess what?
It's not green! LMAO!
2/16/15 -- From his mailbag this morning:
"Advaxis didn't misstate clinical trial results. You're reading too much into my column if you believe I hyped the company's stock or its cancer immunotherapy pipeline. I wrote about Advaxis' chief medical officer joining from Merck and the company's partnership with the Big Pharma giant because I thought these aspects of the bull thesis were over-looked and potentially meaningful."
I couldn't get over how much it was posted time and time and time again.
The biggest pump I think I've ever seen. Ever!
J&E, in just a few paragraphs, how would you compare and contrast ADXS and ZIOP from a technical solution perspective and from a business perspective (e.g. PPS appreciation potential). TIA!
Form 8-K for IDERA PHARMACEUTICALS, INC.
Entry into a Material Definitive Agreement, Other Events, Financial S
Item 1.01. Entry into a Material Definitive Agreement
On February 12, 2015, Idera Pharmaceuticals, Inc. (the "Company") entered into an underwriting agreement (the "Underwriting Agreement") with Goldman, Sachs & Co. and J.P. Morgan Securities LLC, as representatives of the several underwriters (collectively, the "Underwriters"), related to an underwritten public offering of 20,000,000 shares of the Company's common stock, par value $0.001 per share (the "Common Stock"). The public offering price for the Common Stock is $3.75 per share. The underwriters have agreed to purchase the shares pursuant to the Underwriting Agreement at a price of $3.525 per share. The Company has also granted to the Underwriters a 30-day option to purchase up to an additional 3,000,000 shares of Common Stock at the same price per share. All of the shares in the offering are to be sold by the Company.
The Common Stock will be issued pursuant to a prospectus supplement dated February 12, 2015 and an accompanying base prospectus dated May 22, 2014 that form a part of the registration statement on Form S-3 that the Company filed with the Securities and Exchange Commission, which became effective May 22, 2014 (File No. 333-195896). The Company expects that the closing of the sale of the Common Stock will take place on February 19, 2015, subject to the satisfaction of customary closing conditions.
A copy of the Underwriting Agreement is attached as Exhibit 1.1 hereto and is incorporated herein by reference. The foregoing description of the Underwriting Agreement does not purport to be complete and is qualified in its entirety by reference to Exhibit 1.1.
A copy of the legal opinion and consent of Wilmer Cutler Pickering Hale and Dorr LLP relating to the validity of the Common Stock to be issued in the offering is attached as Exhibit 5.1 hereto.
Item 8.01. Other Even